Hepatology International

, Volume 13, Issue 1, pp 66–74 | Cite as

Treatment with direct-acting antivirals improves the clinical outcome in patients with HCV-related decompensated cirrhosis: results from an Italian real-life cohort (Liver Network Activity—LINA cohort)

  • Ivan Gentile
  • Riccardo ScottoEmail author
  • Carmine Coppola
  • Laura Staiano
  • Daniela Caterina Amoruso
  • Teresa De Simone
  • Federica Portunato
  • Stefania De Pascalis
  • Salvatore Martini
  • Margherita Macera
  • Giulio Viceconte
  • Grazia Tosone
  • Antonio Riccardo Buonomo
  • Guglielmo Borgia
  • Nicola Coppola
Original Article



Direct-acting antivirals (DAAs) are safe and effective for the treatment of HCV infection. However, data regarding their efficacy in patients with Child–Pugh B cirrhosis are scarce and their capability in improving liver function is debated. The aim of our study was to assess the clinical benefits of treatment with DAA in subjects with Child–Pugh B cirrhosis.


We conducted a prospective multicentre study among patients with Child–Pugh B cirrhosis of an Italian real-life HCV cohort (LINA cohort) who received treatment with DAAs.


Among 89 patients enrolled, the rate of sustained virologic response 12 was 95.5%. No discontinuation occurred, no patient died during treatment. Most patients had Genotype 1 (1b 61.8%, 1a 11.2%). Conversely, 22.5%, 1.1% and 3.4% of patients had Genotype 2, 3 and 4, respectively. At last observation, 61.8% of patients switched to a Class A cirrhosis, 33.7% remained in Class B and 4.5 worsened to Child C (p < 0.001). Liver parameters significantly improved from baseline to 12 weeks after the end of treatment. Previous anti-HCV treatments and the presence of decompensated cirrhosis at 1 month of treatment were significantly associated with a decompensated cirrhosis at the last observation.


Treatment with DAA in patients with Child–Pugh B cirrhosis is safe and leads to a very high rate of viral clearance, a significant rate of re-compensation and an improvement in liver function. Further studies are needed to assess the impact of treatment on survival and quality of life in long-term follow-up.


Direct-acting antivirals Hepatitis C virus Decompensated cirrhosis 



Not applicable.

Compliance with ethical standards

Conflict of interest

Ivan Gentile was consultant for Abbvie, Merck Sharp & Dohme and Cardiome. He received a grant (in the framework of Fellowship program) from Gilead Sciences. Guglielmo Borgia was consultant for Abbvie. He received grants from Abbvie, Merck Sharp & Dohme, Pfizer. Nicola Coppola received grants from ViiV Healthcare, Janssen-Cilag, and Gilead Sciences; personal fees from Gilead Sciences, Abbvie, Bristol-Myers Squibb and Merck Sharp & Dohme. Riccardo Scotto, Carmine Coppola, Laura Staiano, Daniela Caterina Amoruso, Teresa De Simone, Federica Portunato, Stefania De Pascalis, Salvatore Martini, Margherita Macera, Giulio Viceconte, Grazia Tosone and Antonio Riccardo Buonomo have no conflict of interest to declare.

Ethical approval

All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1975, as revised in 2008.

Informed consent

Informed consent was obtained from all patients for being included in the study.

Supplementary material

12072_2018_9914_MOESM1_ESM.pdf (54 kb)
Longitudinal changes in laboratory parameters through the different follow-up visits (PDF 54 kb)


  1. 1.
    Borgia G, Maraolo AE, Buonomo AR, Scotto R, Gentile I. The therapeutic potential of new investigational hepatitis C virus translation inhibitors. Expert Opin Investig Drugs 2016;25(10):1209–1214CrossRefGoogle Scholar
  2. 2.
    Gentile I, Maraolo AE, Buonomo AR, Zappulo E, Borgia G. The discovery of sofosbuvir: a revolution for therapy of chronic hepatitis C. Expert Opin Drug Discov 2015;10(12):1363–1377CrossRefGoogle Scholar
  3. 3.
    Gentile I, Scotto R, Zappulo E, Buonomo AR, Pinchera B, Borgia G. Investigational direct-acting antivirals in hepatitis C treatment: the latest drugs in clinical development. Expert Opin Investig Drugs 2016;25(5):557–572CrossRefGoogle Scholar
  4. 4.
    Curry MP, Tapper EB, Bacon B, et al. Effectiveness of 8- or 12-weeks of ledipasvir and sofosbuvir in real-world treatment-naive, genotype 1 hepatitis C infected patients. Aliment Pharmacol Ther 2017;46(5):540–548CrossRefGoogle Scholar
  5. 5.
    Nelson DR, Cooper JN, Lalezari JP, et al. All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study. Hepatology (Baltimore, MD) 2015;61(4):1127–1135CrossRefGoogle Scholar
  6. 6.
    Bonora S, Puoti M. Use of daclatasvir in HCV/HIV-coinfected patients in a real-life setting. AIDS Rev 2017;19(1):24–34Google Scholar
  7. 7.
    Hezode C, Asselah T, Reddy KR, et al. Ombitasvir plus paritaprevir plus ritonavir with or without ribavirin in treatment-naive and treatment-experienced patients with genotype 4 chronic hepatitis C virus infection (PEARL-I): a randomised, open-label trial. Lancet (London, England) 2015;385(9986):2502–2509CrossRefGoogle Scholar
  8. 8.
    Andreone P, Colombo MG, Enejosa JV, et al. ABT-450, ritonavir, ombitasvir, and dasabuvir achieves 97% and 100% sustained virologic response with or without ribavirin in treatment-experienced patients with HCV genotype 1b infection. Gastroenterology 2014;147(2):359–365CrossRefGoogle Scholar
  9. 9.
    Mendizabal M, Haddad L, Gallardo PE, et al. Ombitasvir/paritaprevir/ritonavir/dasabuvir ± ribavirin is safe and effective in HCV-infected patients in a real-life cohort from Latin America. J Med Virol 2017;89(9):1590–1596CrossRefGoogle Scholar
  10. 10.
    Gheorghe L, Iacob S, Curescu M, et al. Real-life use of 3 direct-acting antiviral regimen in a large cohort of patients with genotype-1b HCV compensated cirrhosis. J Gastrointest Liver Dis JGLD 2017;26(3):275–281Google Scholar
  11. 11.
    Manns M, Samuel D, Gane EJ, et al. Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trial. Lancet Infect Dis 2016;16(6):685–697CrossRefGoogle Scholar
  12. 12.
    Poordad F, Schiff ER, Vierling JM, et al. Daclatasvir with sofosbuvir and ribavirin for hepatitis C virus infection with advanced cirrhosis or post-liver transplantation recurrence. Hepatology (Baltimore, MD) 2016;63(5):1493–1505CrossRefGoogle Scholar
  13. 13.
    Younossi ZM, Stepanova M, Charlton M, et al. Patient-reported outcomes with sofosbuvir and velpatasvir with or without ribavirin for hepatitis C virus-related decompensated cirrhosis: an exploratory analysis from the randomised, open-label ASTRAL-4 phase 3 trial. Lancet Gastroenterol Hepatol 2016;1(2):122–132CrossRefGoogle Scholar
  14. 14.
    Fernandez Carrillo C, Lens S, Llop E, et al. Treatment of hepatitis C virus infection in patients with cirrhosis and predictive value of model for end-stage liver disease: analysis of data from the Hepa-C registry. Hepatology (Baltimore, MD) 2017;65(6):1810–1822CrossRefGoogle Scholar
  15. 15.
    Maan R, van Tilborg M, Deterding K, et al. Safety and effectiveness of direct-acting antiviral agents for treatment of patients with chronic hepatitis C virus infection and cirrhosis. Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc 2016;14(12):1821–1830Google Scholar
  16. 16.
    Foster GR, Irving WL, Cheung MC, et al. Impact of direct acting antiviral therapy in patients with chronic hepatitis C and decompensated cirrhosis. J Hepatol 2016;64(6):1224–1231CrossRefGoogle Scholar
  17. 17.
    Pascasio JM, Vinaixa C, Ferrer MT, et al. Clinical outcomes of patients undergoing antiviral therapy while awaiting liver transplantation. J Hepatol 2017;67(6):1168–1176CrossRefGoogle Scholar
  18. 18.
    Buonomo AR, Scotto R, Pinchera B, et al. Epidemiology and risk factors for hepatitis C virus genotypes in a high prevalence region in Italy. New Microbiol 2018;41(1):26–29Google Scholar
  19. 19.
    National Institutes of Health. Common terminology criteria for adverse events (CTCAE) version 4.0. Accessed Aug 2018
  20. 20.
    Lawitz E, Poordad F, Gutierrez JA, et al. Simeprevir, daclatasvir and sofosbuvir for hepatitis C virus-infected patients with decompensated liver disease. J Viral Hepat 2017;24(4):287–294CrossRefGoogle Scholar
  21. 21.
    Chang CY, Nguyen P, Le A, et al. Real-world experience with interferon-free, direct acting antiviral therapies in Asian Americans with chronic hepatitis C and advanced liver disease. Medicine 2017;96(6):e6128CrossRefGoogle Scholar
  22. 22.
    Rincon D, Ripoll C, Lo Iacono O, et al. Antiviral therapy decreases hepatic venous pressure gradient in patients with chronic hepatitis C and advanced fibrosis. Am J Gastroenterol 2006;101(10):2269–2274CrossRefGoogle Scholar
  23. 23.
    Roberts S, Gordon A, McLean C, et al. Effect of sustained viral response on hepatic venous pressure gradient in hepatitis C-related cirrhosis. Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc 2007;5(8):932–937Google Scholar
  24. 24.
    de Franchis R. Expanding consensus in portal hypertension: report of the Baveno VI Consensus Workshop: stratifying risk and individualizing care for portal hypertension. J Hepatol 2015;63(3):743–752CrossRefGoogle Scholar
  25. 25.
    Hernandez-Gea V, Aracil C, Colomo A, et al. Development of ascites in compensated cirrhosis with severe portal hypertension treated with beta-blockers. Am J Gastroenterol 2012;107(3):418–427CrossRefGoogle Scholar
  26. 26.
    Schwabl P, Mandorfer M, Steiner S, et al. Interferon-free regimens improve portal hypertension and histological necroinflammation in HIV/HCV patients with advanced liver disease. Aliment Pharmacol Ther 2017;45(1):139–149CrossRefGoogle Scholar
  27. 27.
    Backus LI, Belperio PS, Shahoumian TA, Mole LA. Direct-acting antiviral sustained virologic response: impact on mortality in patients without advanced liver disease. Hepatology 2018;68(3):827–838CrossRefGoogle Scholar
  28. 28.
    Gentile I, Buonomo AR, Scotto R, Zappulo E, Borgia G. Infections worsen prognosis of patients with cirrhosis irrespective of the liver disease stage. Eur J Intern Med 2017;46:e45–e47CrossRefGoogle Scholar
  29. 29.
    Kanwal F, Kramer J, Asch SM, Chayanupatkul M, Cao Y, El-Serag HB. Risk of hepatocellular cancer in HCV patients treated with direct-acting antiviral agents. Gastroenterology 2017;153(4):996–1005CrossRefGoogle Scholar
  30. 30.
    Buonomo AR, Gentile I, Borgia G. Direct acting antiviral agents and hepatocellular carcinoma development: don’t take it for granted. Transl Gastroenterol Hepatol 2017;2:101CrossRefGoogle Scholar
  31. 31.
    World Health Organization. Combating hepatitis B and C to reach elimination by 2030. Advocacy Brief. 2016. Accessed Mar 2018

Copyright information

© Asian Pacific Association for the Study of the Liver 2018

Authors and Affiliations

  • Ivan Gentile
    • 1
  • Riccardo Scotto
    • 1
    Email author
  • Carmine Coppola
    • 2
  • Laura Staiano
    • 2
  • Daniela Caterina Amoruso
    • 2
  • Teresa De Simone
    • 2
  • Federica Portunato
    • 3
  • Stefania De Pascalis
    • 3
  • Salvatore Martini
    • 3
  • Margherita Macera
    • 3
  • Giulio Viceconte
    • 1
  • Grazia Tosone
    • 1
  • Antonio Riccardo Buonomo
    • 1
  • Guglielmo Borgia
    • 1
  • Nicola Coppola
    • 3
  1. 1.Section of Infectious Diseases, Department of Clinical Medicine and SurgeryUniversity of Naples Federico IINaplesItaly
  2. 2.Unit of Hepatology and Interventional Ultrasonography, Department of Internal MedicineOORR Area Stabiese, Plesso Nuovo GragnanoNaplesItaly
  3. 3.Infectious Diseases Unit, Department of Mental Health and Public MedicineUniversity of Campania Luigi VanvitelliCasertaItaly

Personalised recommendations